

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 55718

**Title:** Real-world safety and effectiveness of sofosbuvir and ribavirin for elderly patients over 75 years old

**Reviewer's code:** 03887990

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Academic Research

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2020-04-10

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-04-10 08:43

**Reviewer performed review:** 2020-04-11 15:10

**Review time:** 1 Day and 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

This study evaluated the safety and efficacy of Sofosbuvir plus ribavirin especially for elderly patients in a real-world setting. **Title:** The authors used the term “elderly patients over 75 Years”. The authors included patients above and below 75 Years (range 17-86). Thus, this titled is misleading and showed that the authors included only patients over 75 Years. **Abstract:** The study aim is also focused on the elderly patients over 75 years. It should be modified to include the comparison of patients above and below 75 years. The order of reporting the results is not accurate. The authors started by the patient’s discontinuation and ended by the SVR. The authors should reorder the information by reporting the SVR results then the safety results. **Introduction:** -It should be consistent and directly related to the topic in good writing flow. More than 60% of the reported data related to the ribavirin dose reduction, which was not the main core of this study. They did not report any information related to the study treatment regimen (sofosbuvir plus ribavirin) -Only 3 references in the introduction means lack of information page 5, line 9: please report the other side effects of ribavirin **Methods:** - No sample size calculation and justification was provided - the anthers conducted this study Between June 2015 and June 2017, why they did not include the results of long-term follow-up instead on only SVR12. Reporting the results of relapse or re infection is important. - Study flow diagram of included patients should be provided as per the STROBE checklist to determine the number of screened patients, patients completed the study, patients discontinued, patient’s response. - logistic regression analysis might be effective to determine the most important factors for SVR. - study endpoint should be determined clearly in the methods - definition of the treatment failure should be included. **Results:** - The most important baseline chch should be reported in the rest of the results section. - Treatment effectiveness should be reported

before the safety. - Treatment response section should be written again to be for clear.  
Discussion: Clear and comprehensive      General: the overall manuscript is good but it  
needs careful medical writing revision.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 55718

**Title:** Real-world safety and effectiveness of sofosbuvir and ribavirin for elderly patients over 75 years old

**Reviewer's code:** 04870360

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Lecturer, Research Scientist

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2020-04-10

**Reviewer chosen by:** Jie Wang (Quit in 2020)

**Reviewer accepted review:** 2020-04-15 07:17

**Reviewer performed review:** 2020-04-21 16:45

**Review time:** 6 Days and 9 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

Regarding the manuscript entitled “Real-world safety and effectiveness of sofosbuvir and ribavirin for elderly patients over 75 years old”, the authors evaluated the safety and efficacy of Sofosbuvir plus ribavirin in old age patients and they concluded that this combination is safe and effective in the treatment of HCV infection in elder patients. This manuscript is of interest but contains many problems that required substantial modification: 1- The title is not confirmed with the manuscript methodology. It should be rewritten. 2- The aim of the study is not clear and need to be related to the methodology used. 3- Sample size calculation is missed. 4- The introduction section only one side effect of ribavirin, I recommended to mention the other side effect as well as the side effect of sofosbuvir. 5- Also, introduction section required more references to provide the accurate information. 6- Organization of results section is not accurate, please rewrite again. 7- There are some English errors; I recommended grammar and typos errors revisions. 8- Figure legends should contain full explanatory data, please complete it

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 55718

**Title:** Real-world safety and effectiveness of sofosbuvir and ribavirin for elderly patients over 75 years old

**Reviewer's code:** 02861305

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Academic Research, Associate Professor, Doctor

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2020-04-10

**Reviewer chosen by:** Jie Wang (Quit in 2020)

**Reviewer accepted review:** 2020-04-15 06:42

**Reviewer performed review:** 2020-04-21 20:39

**Review time:** 6 Days and 13 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

It is good study. A study to support the drug use of elderly patients. The number of patients could be higher. it would be better if there were more patients

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 55718

**Title:** Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75 years old and over

**Reviewer's code:** 04870360

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Lecturer, Research Scientist

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** Japan

**Manuscript submission date:** 2020-04-10

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-07-01 07:44

**Reviewer performed review:** 2020-07-01 11:25

**Review time:** 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS





**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

The manuscript has been improved. I accept all the author revisions.